Who are AMDC-USR (iltamiocel)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Platelet Rich Plasma (PRP), Low-dose PRP, 3ml-Rejuvinex, SkinTE, Autologous platelets rich plasma, Leukocyte rich platelet rich plasma.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amdc-usr-iltamiocel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AMDC-USR (iltamiocel) — Competitive Intelligence Brief

AMDC-USR (iltamiocel) (AMDC-USR (iltamiocel)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous cell therapy. Area: Cardiovascular.

phase 3 Autologous cell therapy Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

AMDC-USR (iltamiocel) (AMDC-USR (iltamiocel)) — Cook MyoSite. AMDC-USR (iltamiocel) is an autologous skeletal myoblast cell therapy that regenerates damaged heart muscle tissue following myocardial infarction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
AMDC-USR (iltamiocel) TARGET	AMDC-USR (iltamiocel)	Cook MyoSite	phase 3	Autologous cell therapy
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
Low-dose PRP	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product
3ml-Rejuvinex	3ml-Rejuvinex	Seoul National University Bundang Hospital	marketed	Autologous cell therapy
SkinTE	SkinTE	PolarityTE	marketed	Autologous cell therapy / Tissue-engineered product
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous cell therapy class)

Tetec AG · 2 drugs in this class
GC Cell Corporation · 1 drug in this class
Seoul National University Bundang Hospital · 1 drug in this class
Sewon Cellontech Co., Ltd. · 1 drug in this class
StemCyte, Inc. · 1 drug in this class
TiGenix n.v. · 1 drug in this class
Cook MyoSite · 1 drug in this class
UnicoCell Biomed CO. LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMDC-USR (iltamiocel) — Competitive Intelligence Brief. https://druglandscape.com/ci/amdc-usr-iltamiocel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab